Revolution Medicines (RVMD) News Today $40.29 +0.39 (+0.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a TurnaroundJanuary 17 at 5:08 PM | msn.comRevolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 12:20 PM | insidermonkey.comBarclays Reaffirms Their Buy Rating on Revolution Medicines (RVMD)January 16 at 8:13 PM | markets.businessinsider.comRevolution Medicines' SWOT analysis: stock poised for growth amid clinical trialsJanuary 16 at 8:13 PM | msn.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4.6% - Should You Sell?Revolution Medicines (NASDAQ:RVMD) Trading Down 4.6% - Should You Sell?January 16 at 6:24 PM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4.6% - Here's WhyRevolution Medicines (NASDAQ:RVMD) Trading Down 4.6% - Should You Sell?January 14, 2025 | marketbeat.comRevolution Medicines price target raised to $71 from $65 at UBSJanuary 8, 2025 | markets.businessinsider.comUBS Group Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $71.00UBS Group upped their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a report on Wednesday.January 8, 2025 | marketbeat.comRevolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Rating of "Buy" by AnalystsShares of Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy rating and one has issJanuary 2, 2025 | marketbeat.comJefferies Keeps Their Buy Rating on Revolution Medicines (RVMD)December 20, 2024 | markets.businessinsider.comJack Anders Sells 2,635 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockDecember 19, 2024 | insidertrades.comRevolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders Sells 2,635 SharesRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) CFO Jack Anders sold 2,635 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now owns 96,470 shares of the company's stock, valued at $4,379,738. This trade represents a 2.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.December 18, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) COO Sells $196,536.60 in StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret A. Horn sold 4,329 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total transaction of $196,536.60. Following the sale, the chief operating officer now directly owns 127,991 shares of the company's stock, valued at approximately $5,810,791.40. This represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.December 18, 2024 | marketbeat.comMark A. Goldsmith Sells 11,714 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) StockRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark A. Goldsmith sold 11,714 shares of Revolution Medicines stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $531,815.60. Following the transaction, the insider now directly owns 325,056 shares of the company's stock, valued at $14,757,542.40. The trade was a 3.48 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.December 18, 2024 | marketbeat.comWilmington Savings Fund Society FSB Purchases Shares of 17,667 Revolution Medicines, Inc. (NASDAQ:RVMD)Wilmington Savings Fund Society FSB acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,667 shares of the company's stock, valued atDecember 16, 2024 | marketbeat.comGeode Capital Management LLC Grows Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)Geode Capital Management LLC lifted its position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 8.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,627,025 shares of the company's stock after pDecember 16, 2024 | marketbeat.comBarclays PLC Has $13.36 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Barclays PLC grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 187.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 294,664 shares of the company's stock after acquiringDecember 16, 2024 | marketbeat.comInsiders Are Loving These 6 Stocks Right NowDecember 15, 2024 | 247wallst.comOne Revolution Medicines Insider Raised Their Stake In The Previous YearDecember 12, 2024 | finance.yahoo.comState Street Corp Acquires 208,516 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)State Street Corp raised its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 4.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,279,584 shares of the company's stock after purchasingDecember 12, 2024 | marketbeat.comVerition Fund Management LLC Buys New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Verition Fund Management LLC purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,226 shares of the company's stock, valued at approximaDecember 11, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Director Acquires $59,999,962.00 in StockDecember 10, 2024 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $9.80 Million Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 10.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fundDecember 9, 2024 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from AnalystsRevolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has been given a consensus rating of "Buy" by the twelve ratings firms that are covering the stock, MarketBeat.com reports. Eleven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendatiDecember 8, 2024 | marketbeat.comHC Wainwright Has Positive Forecast for RVMD FY2024 EarningsRevolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 EPS estimates for Revolution Medicines in a report released on Wednesday, December 4th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($3.40) per shDecember 6, 2024 | marketbeat.comPromising Outlook for Revolution Medicines: Strong Efficacy and Safety Data Boost Confidence in RMC-6236 and RMC-6291December 6, 2024 | markets.businessinsider.comRevolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesDecember 5, 2024 | globenewswire.comRevolution Medicines Prices 14.13 Mln Shares At $46/Shr, To Raise $750 MlnDecember 5, 2024 | markets.businessinsider.comJanus Henderson Group PLC Has $278.28 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Janus Henderson Group PLC boosted its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 32.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,137,244 shares of the compDecember 4, 2024 | marketbeat.com27,400 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Erste Asset Management GmbHErste Asset Management GmbH bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 27,400 shares of the company's stock, valued at approximatelyDecember 4, 2024 | marketbeat.comEdgestream Partners L.P. Buys New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD)Edgestream Partners L.P. purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 38,482 shares of the company's stock, vaDecember 4, 2024 | marketbeat.comRevolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded WarrantsDecember 3, 2024 | globenewswire.comHighVista Strategies LLC Raises Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)HighVista Strategies LLC increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 38.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,562 shares of the company's stock after buying an additionDecember 3, 2024 | marketbeat.comCinctive Capital Management LP Has $2.42 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)Cinctive Capital Management LP increased its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 132.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 53,361 shares of the company's stock after acquiring an additionDecember 3, 2024 | marketbeat.comPromising Efficacy and Favorable Safety Profile Drive Buy Rating for Revolution Medicines’ RMC-6236 in NSCLC TreatmentDecember 2, 2024 | markets.businessinsider.comRevolution Medicines provides updates from RAS(ON) inhibitor portfolioDecember 2, 2024 | markets.businessinsider.comRevolution Medicines Announces Commencement of Public Offering of Common StockDecember 2, 2024 | globenewswire.comRevolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor PortfolioDecember 2, 2024 | globenewswire.comFmr LLC Increases Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)Fmr LLC lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 4.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,875,893 shares of the company's stock aftDecember 2, 2024 | marketbeat.comCitigroup Inc. Has $5.35 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)Citigroup Inc. raised its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 29.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 117,938 shares of the company's stock after acquiring an additional 26,871 sharesDecember 2, 2024 | marketbeat.comBellevue Group AG Sells 157,740 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Bellevue Group AG lowered its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 3.1% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 4,871,360 shares of the company's stock after selling 157,740 shares during the period. RevolutiDecember 1, 2024 | marketbeat.comWalleye Capital LLC Acquires 99,589 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Walleye Capital LLC lifted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 44.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 323,732 shares of theNovember 30, 2024 | marketbeat.comEventide Asset Management LLC Sells 127,775 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)Eventide Asset Management LLC reduced its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 19.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 523,051 shares of the company's stock afNovember 29, 2024 | marketbeat.com163,500 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Ally Bridge Group NY LLCAlly Bridge Group NY LLC acquired a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 163,500 shares of the company's stock, valued at approximNovember 28, 2024 | marketbeat.comAcuta Capital Partners LLC Has $4.90 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Acuta Capital Partners LLC trimmed its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 18.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,000 shares of the company'sNovember 28, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)Charles Schwab Investment Management Inc. increased its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 58.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,763,117 shares of the company's stock after buying an aNovember 28, 2024 | marketbeat.comRevolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024November 27, 2024 | globenewswire.com10,164 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Advantage Alpha Capital Partners LPAdvantage Alpha Capital Partners LP purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,164 shares of the company's stock, valued at approximately $461,000. OtheNovember 27, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys New Position in Revolution Medicines, Inc. (NASDAQ:RVMD)Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 26,901 shares of the company's stock, valued at approximNovember 27, 2024 | marketbeat.com Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RVMD Media Mentions By Week RVMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼0.280.57▲Average Medical News Sentiment RVMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼66▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News TEVA News BGNE News GMAB News VTRS News ITCI News MRNA News SMMT News RDY News CTLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
